Regulatory News
Tuesday, September 20, 2016
BRIEF-Bristol-Myers says EMA validates type II variation application for Opdivo
* European Medicines Agency validates Bristol Myers Squibb's
type II variation application for Opdivo (nivolumab) in advanced
form of bladder cancer
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment